Real-World Prevalence of Type 2 Diabetes Remission in a U.S. Insured Population Using a Large Administrative Claims Database.

Objective: A 2021 international consensus statement defined type 2 diabetes remission as A1C <6.5% measured at least 3 months after cessation of glucose-lowering therapy. We aimed to investigate whether retrospective claims-based data can assess remission based on this definition, whether three increasingly strict alternative definitions affect the prevalence of remission and characteristics of remission cohorts, and how cohorts with and without sufficient data to assess for remission differ.

Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance.

Background: Several vaccines with demonstrated efficacy for coronavirus disease 2019 (Covid-19) are available. The purpose of this study was to evaluate the COVID mRNA based and adenovector based vaccines' differential effectiveness during the time of circulation of the Delta variant and determine what impact this would have on population health and cost effectiveness.

Methods: We used de-identified claims in a research database that included vaccination status and Covid-positivity status.

The Development of a Measure Assessing U.S. Adults' Motives for Marriage.

Despite the existing literature assessing various aspects of marriage, there is a lack of understanding of adults' motives for pursuing marriage. Thus, this research advanced the literature by assessing adults' motives for marriage via four novel studies in which the Motives for Marriage Scale (MMS) was developed, refined, and validated. In study one, semi-structured focus groups were conducted to capture the range of motives for marriage.

Medication Fill Patterns for Cognitive and Behavioral or Psychological Symptoms of Alzheimer Disease and Related Dementias.

This cohort study investigates prescription drug fill patterns for cognitive and behavioral symptoms among patients with Alzheimer disease and related dementias.

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine.

Real-world analysis of the incidence of SARS-CoV-2 infection post vaccination is important in determining the comparative effectiveness of the available vaccines. In this retrospective cohort study using deidentified administrative claims for Medicare Advantage and commercially insured individuals in a research database we examine over 3.5 million fully vaccinated individuals, including 8,848 individuals with SARS-CoV-2 infection, with a follow-up period between 14 and 151 days after their second dose.